Inquiry Basket
Loading ......
Deruxtecan is a highly potent anti-cancer compound most commonly used as the cytotoxic payload in antibody–drug conjugates (ADCs). Rather than being administered as a traditional standalone chemotherapy drug, it is chemically linked to a monoclonal antibody that directs it to specific cancer cells. Once delivered inside the tumor cell, deruxtecan interferes with DNA replication and ultimately induces cell death. This targeted delivery strategy has expanded treatment possibilities across multiple solid tumors, particularly those driven by HER2 expression or mutation.
Figure 1. Innovation and challenges of derutecan-driven antibody-drug conjugates in the field of oncology.(Sources: Jang JY, et al.; 2025)
At the molecular level, deruxtecan is a derivative of exatecan and functions as a topoisomerase I inhibitor. Topoisomerase I plays a crucial role in relieving torsional stress in DNA during replication and transcription. By stabilizing the DNA–topoisomerase I complex, deruxtecan prevents proper DNA repair and leads to lethal DNA strand breaks.
Because of its strong cytotoxic potency, deruxtecan is especially suitable for ADC platforms. The antibody component ensures selective tumor targeting, while the linker enables controlled release within the cancer cell. Once released, deruxtecan exerts its effect intracellularly. Its membrane-permeable nature also allows for a bystander effect, meaning it can diffuse into nearby tumor cells and enhance overall tumor killing, even in heterogeneous cancers.
The most recognized clinical use of deruxtecan is in trastuzumab deruxtecan, an ADC targeting HER2 (human epidermal growth factor receptor 2). HER2 is overexpressed in a subset of breast cancers and is associated with aggressive disease behavior.
Trastuzumab deruxtecan has become an important treatment option for patients with HER2-positive metastatic breast cancer, particularly after progression on prior HER2-targeted therapies. Clinical trials have demonstrated significant response rates and durable disease control in heavily pretreated populations.
Importantly, its application has extended to HER2-low breast cancer, a category previously not considered eligible for HER2-directed therapies. This development marked a shift in clinical practice, redefining how HER2 expression levels are interpreted and expanding targeted treatment to a broader patient population.
In certain treatment settings, patients with hormone receptor–positive, HER2-negative metastatic breast cancer may also be considered for deruxtecan-based therapy depending on biomarker profile and prior therapy history. This reflects the broader movement toward biomarker-driven oncology.
HER2-positive gastric and gastroesophageal junction cancers represent another approved indication. In patients who have progressed on prior treatments, trastuzumab deruxtecan has demonstrated improved response rates compared with conventional chemotherapy in selected clinical scenarios.
Gastric cancer often presents with heterogeneous HER2 expression, which can limit the effectiveness of earlier HER2-targeted approaches. The design of deruxtecan-based ADCs, including their bystander effect, helps address some of these biological challenges.
Deruxtecan is also used in patients with non-small cell lung cancer (NSCLC) harboring HER2 mutations. Unlike HER2 overexpression, HER2 mutations function as oncogenic drivers in a subset of lung cancers.
Historically, targeted treatment options for HER2-mutant NSCLC were limited. The development of HER2-directed ADC therapy has provided a more precise and effective option for these patients. Clinical studies have shown meaningful tumor responses in this molecularly defined group.
While trastuzumab deruxtecan is the most well-known example, deruxtecan serves a broader role as a platform payload in next-generation ADC development.
Datopotamab deruxtecan (Dato-DXd) targets TROP2 and is being studied in hormone receptor–positive breast cancer and lung cancer. Patritumab deruxtecan (HER3-DXd, also known as U3-1402) targets HER3 and is under investigation for lung and breast malignancies. In each case, deruxtecan provides the cytotoxic backbone, while the antibody determines tumor specificity.
This modular design allows pharmaceutical developers to apply a validated, high-potency payload across multiple tumor-associated antigens. As a result, deruxtecan has become a foundational component in several oncology pipelines.
Several characteristics explain why deruxtecan has gained prominence in oncology drug development. It exhibits high cytotoxic potency, enabling effective tumor cell killing at low intracellular concentrations. The linker technology used in deruxtecan-based ADCs remains stable in systemic circulation but efficiently releases the drug once inside tumor cells.
Additionally, the relatively high drug-to-antibody ratio enhances payload delivery per targeted cell. The membrane-permeable structure supports a bystander effect, which can improve outcomes in tumors with mixed or variable antigen expression.
These combined features contribute to its strong therapeutic performance across different cancer types.
As with other potent anti-cancer therapies, deruxtecan-based ADCs are associated with adverse effects. Common toxicities may include nausea, fatigue, bone marrow suppression, and hair loss.
A notable safety concern is interstitial lung disease (ILD) or pneumonitis, which has been observed in patients receiving trastuzumab deruxtecan. Early detection and appropriate management are essential to reduce the risk of severe complications. Careful patient monitoring and adherence to clinical guidelines are central to optimizing benefit while minimizing risk.
Deruxtecan is primarily used as the cytotoxic payload in antibody–drug conjugates designed for targeted cancer treatment. Its most established application is in HER2-directed therapies for breast, gastric, and lung cancers. Beyond these approved indications, it serves as a versatile platform for developing novel ADCs against additional tumor-associated targets such as HER3 and TROP2.
By combining potent topoisomerase I inhibition with antibody-guided delivery, deruxtecan-based therapies represent a significant advancement in precision oncology. As research continues, its role in expanding and refining targeted cancer treatment is expected to grow further.
Deruxtecan itself is a cytotoxic chemotherapy agent, specifically a topoisomerase I inhibitor. However, in clinical practice it is not given alone. It is delivered as part of an antibody–drug conjugate (ADC), which makes the overall treatment a form of targeted therapy. The antibody directs deruxtecan specifically to cancer cells expressing a particular biomarker, such as HER2.
Deruxtecan-based ADCs are approved for certain types of breast cancer (including HER2-positive and HER2-low metastatic breast cancer), HER2-positive gastric cancer, and HER2-mutant non-small cell lung cancer. Additional tumor types are being investigated in ongoing clinical trials.
Traditional chemotherapy circulates systemically and affects both cancerous and healthy rapidly dividing cells. Deruxtecan, when used in an ADC, is selectively delivered to tumor cells via a targeting antibody. This design helps improve precision and may enhance anti-tumor activity, particularly in biomarker-defined populations.
After the ADC binds to the target cell and releases deruxtecan inside it, the drug can diffuse into nearby tumor cells. This is known as the bystander effect. It can be beneficial in tumors where not all cells uniformly express the target antigen, potentially improving overall tumor control.
Common adverse effects include nausea, fatigue, decreased blood cell counts, and hair loss. One important but less common risk is interstitial lung disease (ILD) or pneumonitis. Patients receiving these therapies are closely monitored to detect and manage side effects early.
Reference
| Target | Cat. No. | Product Name | Host | Application | |
| DXD | CABT-L828M | Mouse Anti-Dxd monoclonal antibody, clone 13 | Mouse | ELISA | Inquiry |
| CABT-L0103Y | Mouse Anti-DXD&Exatecan monoclonal Antibody, clone N793 | Mouse | PK, PD, IA, ELISA | Inquiry | |
| CABT-L1055X | Anti-DXD monoclonal antibody | Rabbit | ELISA | Inquiry | |
| CABT-L1056X | Anti-DXD monoclonal antibody | Rabbit | ELISA | Inquiry | |
| CABT-L1061X | Anti-DXD monoclonal antibody, Biotin | Rabbit | ELISA | Inquiry | |
| CABT-L1062X | Anti-DXD monoclonal antibody, PE | Rabbit | FC | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| DXD | DEIA-JY25377 | Deruxtecan (Dxd) ADC ELISA Kit | Quantitative | Serum, plasma | Inquiry |
Loading ......
